Your session is about to expire
← Back to Search
Nivolumab for Melanoma
Study Summary
This trial is testing whether a combination of two different drugs may help patients with mucosal melanoma.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver functions well and I don't have severe liver disease.I have had a condition where lymphocytes grow abnormally.I do not have any blood disorders.I haven't had cancer in the last 5 years, except for skin cancer.I haven't had seizures or conditions that could cause them in the last 2 years.My melanoma diagnosis was confirmed by a pathology test.I don't have any stomach or bowel problems affecting medicine absorption.I am not currently receiving treatment for any other cancer.I haven't taken steroids or immunosuppressants in the last 14 days.I do not have any brain metastases.I do not have untreated spinal issues related to cancer.I am not on any strong medication that affects liver enzymes.I have not had immunotherapy for mucosal melanoma.My cancer was surgically removed with clear or close margins.I have a history of cancer.I do not have any heart diseases.I am not on any strong medications that affect liver enzymes.
- Group 1: Arm 2 (nivolumab, placebo)
- Group 2: Arm 3 (nivolumab, cabozantinib)
- Group 3: Arm 1 (nivolumab, cabozantinib)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In what medical scenarios is Nivolumab employed?
"Nivolumab can be deployed to treat highly malignant neoplasms, intractable melanoma and squamous cell carcinoma."
What adverse effects have been associated with Nivolumab treatments?
"Nivolumab is assessed as a 2 on our team's safety scale, since this Phase 2 trial has evidence supporting its security but not yet any data demonstrating efficacy."
What is the highest possible number of people who may partake in this medical experiment?
"To complete this medical trial, 99 participants need to be recruited who fit the qualification criteria. Recruitment will take place at Saint Vincent Hospital Cancer Center Green Bay in Green Bay, Wisconsin and Saint Vincent Hospital Cancer Center at Saint Mary's in Oconto Falls, Illinois."
At what number of venues is this experiment in progress?
"Patients from Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Hospital Cancer Center at Saint Mary's in Oconto Falls and many other locations are currently eligible for enrollment into this trial."
Is the enrollment for this research still open to participants?
"The information provided on clinicaltrials.gov indicates that this experiment is still in the recruitment stage; it was initially posted on June 1st 2022 and its details were most recently updated on November 18th 2022."
Is this the inaugural implementation of a trial such as this?
"Currently, there are 794 active trials for Nivolumab in 53 countries and 2553 cities. This immunotherapy drug was first tested by Exelixis back in 2012 with a Phase 2 study that included 86 participants. Since then, 318 more clinical studies have been completed."
Are there any historical precedents of trials utilizing Nivolumab?
"Nivolumab was first tested in a clinical context at Memorial Sloan Kettering Commack back in 2012. To date, there are 318 concluded trials and an additional 794 ongoing studies being conducted across the United States, notably Green Bay, Wisconsin."
Share this study with friends
Copy Link
Messenger